

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 9/14, 9/72</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/53158</b> <b>(43) International Publication Date:</b> 14 September 2000 (14.09.00)
<b>(21) International Application Number:</b> PCT/EP00/01773 <b>(22) International Filing Date:</b> 2 March 2000 (02.03.00) <b>(30) Priority Data:</b> MI99A000455 5 March 1999 (05.03.99) IT <b>(71) Applicant (for all designated States except US):</b> CHIESI FARMACEUTICI S.p.A [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MUSA, Rossella [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). BILZI, Roberto [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). CHIESI, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). <b>(74) Agents:</b> MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milan (IT).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MODIFIED CARRIER PARTICLES FOR USE IN DRY POWDER INHALERS		
<b>(57) Abstract</b>  The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## MODIFIED CARRIER PARTICLES FOR USE IN DRY POWDER INHALERS

## PRIOR ART

Inhalation anti-asthmatics are widely used in the treatment of reversible airway obstruction, inflammation and hyperresponsiveness.

5       Presently, the most widely used systems for inhalation therapy are the pressurised metered dose inhalers (MDIs) which use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract.

10       However, despite their practicality and popularity, MDIs have some disadvantages:

      i) droplets leaving the actuator orifice could be large or have an extremely high velocity resulting in extensive oropharyngeal deposition to the detriment of the dose which penetrates into the lungs;

15       ii) the amount of drug which penetrates the bronchial tree may be further reduced by poor inhalation technique, due to the common difficulty of the patient to synchronise actuation from the device with inspiration ;

      iii) chlorofluorocarbons (CFCs), such as freons  
20       contained as propellants in MDIs, are disadvantageous on environmental grounds as they have a proven damaging effect on the atmospheric ozone layer.

      Dry powder inhalers (DPIs) constitute a valid alternative to MDIs for the administration of drugs to  
25       airways. The main advantages of DPIs are:

      i) being breath-actuated delivery systems, they do not require co-ordination of actuation since release of the drug is dependent on the patient own inhalation;

      ii) they do not contain propellants acting as  
30       environmental hazards;

iii) the velocity of the delivered particles is the same or lower than that of the flow of inspired air, so making them more prone to follow the air flow than the faster moving MDI particles, thereby reducing upper respiratory tract deposition.

DPIs can be divided into two basic types:

i) single dose inhalers, for the administration of pre-subdivided single doses of the active compound;

ii) multidose dry powder inhalers (MDPIs), pre-loaded with quantities of active ingredient sufficient for multiple doses; each dose is created by a metering unit within the inhaler.

Drugs intended for inhalation as dry powders should be used in the form of micronised powder so they are characterized by particles of few micron particle size ( $\mu\text{m}$ ). Said size is quantified by measuring a characteristic equivalent sphere diameter, known as aerodynamic diameter, which indicates the capability of the particles of being transported suspended in an air stream. Respirable particles are generally considered to be those with diameters from 0.5 to 6  $\mu\text{m}$ , as they are able of penetrating into the lower lungs, i.e. the bronchiolar and alveolar sites, where absorption takes place. Larger particles are mostly deposited in the oropharyngeal cavity so they cannot reach said sites, whereas the smaller ones are exhaled.

Although micronisation of the active drug is essential for deposition into the lower lungs during inhalation, it is also known that the finer the particles, the stronger are the cohesion forces. Strong cohesion forces hinder the handling of the powder during the manufacturing process (pouring, filling). Moreover they reduce the flowability of the particles while favoring the agglomeration and/or adhesion thereof to the walls. In multidose DPI's, said phenomena impair the loading of the powder from the

reservoir to the aerosolization chamber, so giving rise to handling and metering accuracy problems.

Said drawbacks are also detrimental to the respirable fraction of the delivered dose being the active particles unable to leave the inhaler and remaining adhered to the interior of the inhaler or leaving the inhaler as large agglomerates; agglomerated particles, in turn, cannot reach the bronchiolar and alveolar sites of the lungs. The uncertainty as to the extent of agglomeration of the particles between each actuation of the inhaler and also between inhalers and different batches of particles, leads to poor dose reproducibility as well.

In an attempt to improve both the handling and the efficiency, the dry powders for inhalation are generally formulated by mixing the micronised drug with a carrier material (generally lactose, preferably  $\alpha$ -lactose monohydrate) consisting of coarser particles. In such ordered mixtures, the micronised active particles, because of the electrostatic or Van der Waals interactions, mainly adhere to the surface of the carrier particles whilst in the inhaler device; on the contrary, during inhalation, a redispersion of the drug particles from the surface of the carrier particles occurs allowing the formers to reach the absorption site into the lungs.

Nevertheless, the use of a carrier is not free of drawbacks in that the strong interparticle forces between the two ingredients may prevent the separation of the micronised drug particles from the surface of the coarse carrier ones on inhalation, so compromising the availability of the drug to the respiratory tract. The surface of the carrier particles is, indeed, not smooth but has asperities and clefts, which are high energy sites on which the active particles are preferably attracted to and adhere more strongly; because of such strong, interparticle

forces, they will be hardly leave the surface of the carrier particles and be dispersed in the respiratory tract.

Therefore the features of the carrier particles should  
5 be such as to give sufficient adhesion force to hold the active particles to the surface of the carrier particles during manufacturing of the dry powder and in the delivery device before use, but that force of adhesion should be low enough to allow the dispersion of the active particles in  
10 the respiratory tract.

The prior art discloses several approaches for manipulating the interparticle interactions between the drug and the carrier in ordered powder mixtures.

First, the carrier particles can be chosen according  
15 to their median particle size, taking into account the fact that a decrease in median particle size increases the adhesion force between drug and carrier particles.

GB 1,242,211 and GB 1,381,872 disclose pharmaceutical powders for the inhalatory use in which the micronised drug  
20 (0.01 - 10  $\mu\text{m}$ ) is mixed with carrier particles of sizes 30 to 80  $\mu\text{m}$  and 80 to 150  $\mu\text{m}$ , respectively; said mixtures can also contain a diluent of the same particle size as the micronised drug.

The deaggregation of the active ingredient from the  
25 carrier during inhalation can also be made more efficient by modifying the surface properties of the carrier and/or by addition of a fine fraction (<10  $\mu\text{m}$ ), preferably of the same material of the carrier (Podcizek F. *Aerosol Sci. Technol.* 1999, 31, 301-321; Lucas P. et al *Resp. Drug Deliv.* 1998, VI, 243-250).  
30

GB 2,240,337 A discloses, for example, a controlled crystallization process for the preparation of carrier particles with smoother surfaces, and, in particular, characterized by a rugosity of less than 1.75 as measured

by air permeametry; in practice their smoothness is readily apparent under electronic microscope examination. The use of said carrier particles allows to increase the respirable fraction of the drug (Kassem, Doctoral thesis of the London University, 1990).

EP 0,663,815 claims the use of carriers for controlling and optimizing the amount of delivered drug during the aerosolisation phase, consisting of suitable mixtures of particles of size  $> 20 \mu\text{m}$  and finer particles ( $< 10 \mu\text{m}$ ).

Staniforth et al. (WO 95/11666) combine both the aforementioned teachings (i.e. modification of the surface properties of the carrier and addition of a fine fraction) by exploiting the effects of a milling process, preferably carried out in a ball mill, referred to as corrasion. (corrasion is a term used in geology and it describes either the effect of the wind on rocks and the filling of valley with stones during the ice age). Said process modifies the surface properties and it gets rid of the waviness of the carrier particles by dislodging any asperities in the form of small grains without substantially changing the size of the particles; the small grains, in turn, can be reattached to the surfaces of the particles either during the milling phase or after preventive separation followed by mixing, in order to saturate other high energy sites such as clefts. Said preliminary handling of the carrier causes the micronised drug particles to preferably link to the lower energy sites, thus being subjected to weaker interparticle adhesion forces.

Podcěk (*J. Adhesion Sci. Technol.* 1998, 12, 1323-1339), after having studied the influence of the corrasion process on the adhesion forces by blending the carrier with different percentages of fine particle fraction before

addition of the drug, concluded however that such process is not always sufficient to ensure effective redispersion but the latter also depends on the initial surface roughness of the coarse carrier particles.

5        Patent literature also suggests the use of powder formulations for inhalation wherein the adhesion between the carrier particles and the active ingredient particles is further reduced by addition of suitable amounts of suitable additives.

10        In WO 96/23485, particles are mixed with an anti-adherent or anti-friction material consisting of one or more compounds selected from amino acids (preferably leucine); phospholipids or surfactants; the amount of additive and the process of mixing are preferably chosen in  
15        such a way as to not give rise to a real coating, but instead a partial coating directed to the high energy sites. The carrier particles blended with the additive are preferably subjected to the corrasion process in a ball mill as disclosed in WO 95/11666.

20        OBJECT OF THE INVENTION

It has now been found, and it is the object of the invention, that it is possible to modify the surface properties of the carrier particles and simultaneously modulate their interaction with the micronised drug  
25        particles by producing in situ a fine fraction of the carrier itself, without submitting the coarse carrier particles to a milling process but by employing a conventional mixer.

The use of a mixer, which intrinsically assures milder  
30        conditions, allows to modify the surface properties of the carrier particles without significantly changing their sizes, crystalline structure and chemico-physical properties.

It has been indeed reported that the chemical



compounds preferably used as carrier, such as lactose, can undergo chemico-physical alterations, when subjected to mechanical stresses, such as milling (Otsuka et al. J. Pharm. Pharmacol. 43, 148-153, 1991).

5        Moreover, hard treatments such as corrasion may moderately reduce the cristallinity of the additives used (Malcolmson R et al. Respiratory Drug Deliv. 1998, VI, 365-367).

10        It has been also surprisingly found that, by virtue of the milder operative conditions of the invention, the fraction of fine particles of size larger than 10  $\mu\text{m}$  is poor, as proved by the particle size analysis via laser diffractometry (Malvern). It is well known that only the fine fraction below 10  $\mu\text{m}$ , once redistributed onto the  
15        surface of the coarse carrier particles, is indeed responsible for the decrease of the interparticle forces, whereas the fine particles of size larger than 10  $\mu\text{m}$ , contribute to decrease the flowability of the powder.

20        On the contrary, milling, as reported above, is a hard process which produces a fine fraction with a much wider particle size distribution which, in turn, could be detrimental for the flow properties of the mixture. Therefore, the powders made with carriers preventively subjected to milling processes could turn out to be not  
25        flowable enough to be suitable for multidose inhalers. Accordingly, the carriers subjected to the milling process often require a further separation step in order to select the fine fraction suitable for being mixed with the coarse carrier particles and discard that one which can be  
30        detrimental to the flow properties of the powder.

By operating according to the process of the present invention, the flow properties of the carrier are not significantly affected, as indicated by the Carr index as well as by the Flodex test. The process of the invention

allows therefore to avoid the further separation step of the fine fraction suitable for being mixed with the coarse carrier particles.

The mixing process of the invention, compared with the milling process as described in WO 95/11666, allows to remarkably reduce the time of treatment. In a preferred embodiment of the invention, carriers with suitable properties are indeed obtained after 30 minutes of treatment in a sigma blade mixer whereas, according to WO 95/11666, carrier particles should be milled for at least one hour and preferably six hours.

Finally, the process of the invention provides a carrier for dry powders for inhalation able of giving good performances in terms of respirable fraction of the drug as demonstrated by the examples reported.

Advantageously the carrier particles are treated in any mixer, of any size and shape, equipped with a rotating element. Preferably the carrier particles are treated in mixers constituted of a stationary or rotating body equipped with any rotatory element (blade, screw) or in the high energy mixers ("high-shear") and blended for a total time ranging from 5 to 360 minutes.

Even more preferably the carrier particles are treated in a sigma-blade mixer at a rate of 100-300 r.p.m and for 30 minutes.

The carrier particles may be constituted of any pharmacologically acceptable inert material or combination thereof; preferred carriers are those made of crystalline sugars, in particular lactose; the most preferred are those made of  $\alpha$ -lactose monohydrate. Advantageously the diameter of the carrier particles lies between 20 and 1000  $\mu\text{m}$ , preferably between 90 and 150  $\mu\text{m}$ .

A further aspect of the invention relates to the preparation of carrier powders in which, after treatment in

a mixer, the carrier particles are mixed with suitable amounts, preferably from 0.05 to 2% by weight, of additives able of further reducing the drug-carrier interparticle forces, thereby increasing the respirable fraction.

5       The additives can be selected from those belonging to the class of the lubricants, such as metal stearates or to the classes of anti-adherent agents or glidants.

      The preferred lubricant is magnesium stearate, but stearic acid, sodium stearyl fumarate and sodium benzoate  
10       can also be used.

      A further aspect of the invention are the formulations for inhalation obtained by mixing the active ingredient particles (with a mean aerodynamic diameter of less than 5 mm) with carrier powders obtained according to the process  
15       of the invention.

      The preferred active particles will be particles of one or mixture of drugs which are usually administered by inhalation for the treatment of respiratory diseases, for example steroids such as beclomethasone dipropionate, flunisolide and budesonide;  $\beta$ -agonists such as salbutamol, formoterol, salmeterol, terbutaline and corresponding  
20       salts; anticholinergics such as ipratropium bromide. Any other active ingredient suitable for pulmonary and/or nasal delivery can be anyway used in these formulations.

25       The process of the invention is illustrated by the following examples.

#### EXAMPLE 1

##### a) Preparation of the carrier

$\alpha$ -Lactose monohydrate with a starting particle size  
30       between 90 to 150  $\mu$ m is mixed for 30 minutes in a sigma blade mixer. At the end of the treatment, only a slight reduction of the particle size is observed.

      The Malvern analysis pattern referring to the particle size distribution of the carrier particles before (- -) and

after (----) the pre-mixing treatment is reported in Figure 1 whereas the relevant data are reported in Table 1.

Table 1. Particle size distribution ( $\mu\text{m}$ )

			Unmixed	Pre-mixed
5	Malvern	d (v, 0.1)	100.4	61.4
		d (v, 0.5)	138.3	127.1
		d (v, 0.9)	197.8	187.7

b) Preparation of the beclomethasone dipropionate (BDP)/lactose binary mixture

10 The carrier powder obtained according to the process a) is mixed with such an amount of micronised beclomethasone dipropionate as to obtain a ratio of 200  $\mu\text{m}$  of active to 26 mg total mixture.

c) Characterization of the mixture

15 The active ingredient/carrier mixture was characterized by its density and flowability parameters.

The poured density (dv) and the tapped density (ds) were calculated as follows. Powder mixtures (20 g) were poured into a glass graduated cylinder and dv was  
20 calculated dividing the weight by the volume; ds was calculated from the volume obtained after tapping the powder mixture 500 times using a commercially available apparatus.

The flowability was evaluated from the Carr's index  
25 calculated according to the following formula:

$$\text{Carr's index (\%)} = \frac{ds - dv}{ds} \times 100$$

30 A Carr index of less than 25 is usually considered indicative of good flowability characteristics.

The flowability properties were also determined by using a Flodex tester. The determination is based upon the ability of the powder mixture to fall freely through holes  
35 of different diameters placed at the bottom of a cylinder.

11

The powder was poured into the cylinder via a powder funnel. The flowability index is given in millimetre diameter of the smallest hole through which the powder falls freely.

5           d) Determination of the aerosol performances.

An amount of powder for inhalation was loaded in a multidose inhaler (Pulvinal<sup>(R)</sup> - Chiesi Pharmaceutical SpA, Italy).

10           The evaluation of the aerosol performances was performed by using a Twin Stage Impinger apparatus, TSI (Apparatus of type A for the aerodynamic evaluation of fine particles described in FU IX, 4<sup>o</sup> supplement 1996). The equipment consists of two different glass elements, mutually connected to form two chambers capable of  
15           separating the powder for inhalation depending on its aerodynamic size; the chambers are referred to as higher (stage 1) and lower (stage 2) separation chambers, respectively. A rubber adaptor secures the connection with the inhaler containing the powder. The apparatus is  
20           connected to a vacuum pump which produces an air flow through the separation chambers and the connected inhaler. Upon actuation of the pump, the air flow carries the particles of the powder mixture, causing them to deposit in the two chambers depending on their aerodynamic diameter.  
25           When the air flow is 60 l/min, the aerodynamic diameter limit value,  $d_{ae}$ , for the deposition in the lower separation chamber is 6.4  $\mu$ m. Particles with higher  $d_{ae}$  deposit in Stage 1 and particles with lower  $d_{ae}$  in Stage 2. In both stages, a minimum volume of solvent is used (30 ml  
30           in Stage 2 and 7 ml in Stage 1) to prevent particles from adhering to the walls of the apparatus and to promote the recovery thereof.

The determination of the aerosol performances of the mixture obtained according to the preparation process b)

12

was carried out with the TSI applying an air flow rate of 60 l/min for 5 seconds.

After nebulization of each dose of the dry powder in the Twin Stage Impinger, the apparatus was disassembled and the amounts of drug deposited in the two separation chambers were recovered by washing with a solvent mixture, then diluted to a volume of 50 ml in two volumetric flasks, one for Stage 1 and one for Stage 2, respectively. The amounts collected in the two volumetric flasks were then determined by High-Performance Liquid Chromatography (HPLC). The following parameters, as mean and relative standard deviations (RSD) of the values obtained from three inhalers, by actuating 5 shots from each inhaler, were calculated: i) the fine particle dose (FPD) which is the amount of drug found in stage 1 of TSI; ii) the emitted dose which is the amount of drug delivered from the device recovered in stage 1 + stage 2; iii) the fine particle fraction (FPF) which is the percentage of the emitted reaching stage 2 of TSI.

The results in terms of technological parameters and aerosol performances are reported in Table 2, in comparison with a similar preparation obtained by mixing the active ingredient with  $\alpha$ -lactose monohydrate lactose 90-150  $\mu$ m not pre-treated in the mixer (standard preparation).

Table 2

Standard Preparation		Preparation of Example 1	
		Technological Parameters	
Apparent Density (g/mL)			
5	- Poured	0.71	0.75
	- Tapped	0.80	0.90
	Flodex test ( $\emptyset$ 4mm)	4	4
Flow rate through			
	$\emptyset$ 4mm (g/min)	67	46
10	Carr Index (%)	11	17
TSI test			
	Mean weight (mg)	22.8 (3.3)	25.6 (2.6)
	Emitted dose ( $\mu$ g)	184.0 (3.3)	165.8 (6.9)
	FPD ( $\mu$ g)	31.0 (50.9)	37.4 (8.9)
15	PPF (%)	16.9 (53.2)	22.7 (10.6)

The results show that the flowability properties of the carrier are not significantly affected even in the presence of a slight reduction of the particle size.

The treatment of the carrier also causes a significant increase of the fine particle fraction (t Student = 2.42, p < 0.005).

#### EXAMPLE 2

Preparation of a salbutamol base/lactose binary mixture

25 Analogously to what described in example 1, a mixture containing micronised salbutamol base as active ingredient in a ratio of 200  $\mu$ g to 24 mg total mixture was prepared.

The poured and tapped densities and the flowability characteristics were determined as described in example 1.  
 30 The dry powder for inhalation was loaded in a Pulvinal<sup>(R)</sup> inhaler and the aerosol performances were determined as described in example 1.

The results are reported in Table 3 in comparison with a similar preparation obtained by mixing the active

ingredient with  $\alpha$ -lactose monohydrate lactose 90-150  $\mu$ m not pre-treated in a mixer (standard preparation).

Table 3

5	Standard preparation	Preparation of Example 2	
		Technological parameters	
	Apparent density (g/mL)		
	- Poured	0.71	0.74
	- Tapped	0.78	0.83
	Flodex test ( $\emptyset$ 4mm)	4	4
10	Flow Rate through		
	$\emptyset$ 4mm (g/min)	72	-
	Carr Index (%)	9	11
	TSI test		
	Mean weight (mg)	22.2 (1.7)	25.2 (3.3)
15	Emitted dose ( $\mu$ g)	185.0 (2.6)	168.2 (4.7)
	FPD ( $\mu$ g)	60.1 (11.6)	80.9 (14.6)
	FPF (%)	32.2 (11.5)	47.9 (11.4)

Also in this case, the results show that the flowability properties of the carrier do not significantly change.

Analogously, a significant increase ( $t = 9.17$ ,  $p < 0.001$ ) of the fine particle fraction is observed with the carrier prepared according to the process a) described in example 1.

### 25 EXAMPLE 3

Preparation of a BDP/lactose/magnesium stearate ternary mixture

The powder carrier was prepared according to Example 1 a) by mixing  $\alpha$ -lactose monohydrate for 30 minutes in a sigma blade mixer. Afterwards lactose was mixed with 0.25% by weight of magnesium stearate in a Turbula mixer for two hours. Finally the dry powder for inhalation was prepared by mixing an amount of micronised beclomethasone dipropionate corresponding to a dose of 200  $\mu$ g and the



15

carrier (lactose + magnesium stearate) for 30 minutes in a Turbula rotating mixer at 32 rpm.

The poured and tapped densities, the flowability characteristics as well as the aerosol performances were  
5 determined as described in example 1.

The results are reported in Table 4 in comparison with a standard formulation obtained by mixing 200  $\mu\text{g}$  of micronised BDP with a carrier powder consisting of 99.75% by weight of  $\alpha$ -lactose monohydrate 90 - 150  $\mu\text{g}$  not pre-  
10 treated in a mixer, and 0.25% by weight of magnesium stearate (standard preparation).

16

Table 4

	Standard preparation	Preparation of Example 3	
		Technological parameters	
	Apparent Density (g/mL)		
5	- Poured	0.76	0.83
	- Tapped	0.81	0.92
	Flodex test (0 4mm)	4	4
	Flow Rate through		
	0 4mm (g/min)	56	42
10	Carr Index (%)	6	10
		TSI test	
	Mean weight (mg)	24.5 (1.5)	27.9 (3.2)
	Emitted dose ( $\mu$ g)	188.9 (4.5)	199.8 (2.2)
	FPD ( $\mu$ g)	48.0 (19.5)	68.9 (5.6)
15	FPF (%)	25.3 (15.3)	34.5 (5.2)

The flowability properties of the carrier do not significantly change even in the presence of a ternary mixture and a significant increase ( $t = 8.29$ ,  $p < 0.001$ ) of the fine particle fraction is observed with the carrier prepared according to the invention.

20


## CLAIMS

1. A process for modifying the surface properties of particles for use as carrier particles for the pulmonary administration of micronised drugs by means of dry powder inhalers, the process including the step of subjecting said carrier particles to a mixing treatment in a mixer equipped with a rotating element in order to produce *in situ* a fine fraction of said carrier.
2. A process according to claim 1, in which the particles of said carrier have a starting diameter ranging from 90 to 150  $\mu\text{m}$  and said fine fraction of the carrier has a mean aerodynamic diameter of less than 10  $\mu\text{m}$ .
3. A process according to claims 1-2 in which the mixer is selected from those with a stationary or rotating body equipped with any rotatory element (blade, screw) or the high energy ones such as "high-shear".
4. A process according to claims 1-3 in which the mixer is a sigma blade mixer and the rate of mixing is comprised between 100 and 300 r.p.m..
5. A process according to claims 1-4, in which the mixing time of the carrier powder ranges from 5 to 360 minutes.
6. A process according to claims 1-5, in which the mixing time is 30 minutes.
7. A process according to claims 1-6, in which said carrier consists of one or more saccharides.
8. A process according to claims 1-7, in which said carrier consists of  $\alpha$ -lactose monohydrate.
9. A process according to claims 1-8, which yields a fraction of carrier particles whose variation of the starting mean aerodynamic diameter is less than 20%.
10. A process according to the preceding claims in which, after mixing in the mixer, a suitable amount of an additive selected from lubricants, anti-adherent agents and glidants is added to the carrier.

18

11. A process according to claim 10, in which the amount of additive ranges from 0.05 to 2%.
12. A process according to claims 10 and 11, in which the lubricant is magnesium stearate, stearic acid, sodium stearyl fumarate or sodium benzoate.
13. A process according to the preceding claims, in which one or more active ingredients, whose particles have a mean diameter of less than 5  $\mu\text{m}$ , are added to the carrier.
14. A process according to claim 13, in which the active ingredient is a  $\beta$ -agonist selected from salbutamol, formoterol, salmeterol, terbutaline or salts thereof.
15. A process according to claim 13, in which the active ingredient is an antiinflammatory steroid selected from beclomethasone dipropionate, flunisolide, budesonide and the epimers thereof.
16. A process according to 13 in which the active ingredient is an anticholinergic selected from ipratropium bromide or oxytropium bromide.

1/1

FIGURE  
%

# INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/EP 00/01773

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K9/14 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 44 25 255 A (ASTA MEDICA AG) 18 January 1996 (1996-01-18)	1-3, 5-9, 13-16
Y	page 2, line 1 - line 5 page 3, line 8 - line 55	10-12
A	WO 95 11666 A (CO-ORDINATED DRUG DEVELOPMENT LTD.) 4 May 1995 (1995-05-04) cited in the application page 12, line 2 -page 18, line 25	1-3, 5-9, 13-16
Y	WO 96 23485 A (CO-ORDINATED DRUG DEVELOPMENT LIMITED) 8 August 1996 (1996-08-08) cited in the application claims 1-49 page 12, line 21 -page 13, line 12 page 17, line 8 -page 23, line 7	10-12
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 July 2000

Date of mailing of the international search report

19/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

# INTERNATIONAL SEARCH REPORT

Int'l. Patent Application No  
PCT/EP 00/01773

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 2 107 715 A (GLAXO GROUP LIMITED (GREAT BRITAIN)) 5 May 1983 (1983-05-05) page 4; example 5	1,3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/01773

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4425255 A	18-01-1996	AU 703924 B	01-04-1999
		AU 2886295 A	16-02-1996
		BR 9508287 A	21-07-1998
		CA 2195065 A	01-02-1996
		CN 1156960 A	13-08-1997
		CZ 9700126 A	18-02-1998
		WO 9602231 A	01-02-1996
		EP 0771189 A	07-05-1997
		FI 970164 A	15-01-1997
		HR 950403 A	31-10-1997
		HU 76807 A	28-11-1997
		JP 3011770 B	21-02-2000
		JP 10502647 T	10-03-1998
		NO 970068 A	08-01-1997
		NZ 289117 A	26-06-1998
		PL 318649 A	07-07-1997
		RU 2140260 C	27-10-1999
		SK 5697 A	04-06-1997
		TR 960058 A	21-06-1996
		ZA 9505892 A	19-02-1996
WO 9511666 A	04-05-1995	AU 706986 B	01-07-1999
		AU 7998194 A	22-05-1995
		CA 2174767 A	04-05-1995
		EP 0725624 A	14-08-1996
		JP 9507049 T	15-07-1997
WO 9623485 A	08-08-1996	AU 699131 B	26-11-1998
		AU 4545696 A	21-08-1996
		BG 101858 A	30-04-1998
		BR 9607490 A	23-12-1997
		CA 2211874 A	08-08-1996
		CZ 9702443 A	14-01-1998
		EP 0806938 A	19-11-1997
		FI 973151 A	30-09-1997
		HU 9802209 A	01-02-1999
		JP 10513174 T	15-12-1998
		NO 973502 A	30-09-1997
		NZ 300654 A	25-02-1999
		PL 321572 A	08-12-1997
		SK 103697 A	14-01-1998
		ZA 9600721 A	19-08-1996
GB 2107715 A	05-05-1983	AU 551471 B	01-05-1986
		AU 8946082 A	03-05-1984
		BE 894725 A	18-04-1983
		CA 1189853 A	02-07-1985
		CH 652134 A	31-10-1985
		DE 3238569 A	05-05-1983
		DK 168389 B	21-03-1994
		ES 516611 D	01-05-1984
		ES 8404374 A	16-07-1984
		FI 823561 A, B,	20-04-1983
		FR 2514769 A	22-04-1983
		HK 100989 A	29-12-1989
		IE 54170 B	05-07-1989
		IT 1196553 B	16-11-1988
		JP 1736919 C	26-02-1993



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01773

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2107715 A		JP 4024358 B	24-04-1992
		JP 58090599 A	30-05-1983
		KR 8900664 B	22-03-1989
		MY 91087 A	31-12-1987
		NL 8204013 A	16-05-1983
		NZ 202212 A	24-01-1986
		PT 75692 A	01-11-1982
		SE 454356 B	25-04-1988
		SE 8205904 A	18-10-1982
		US 4866051 A	12-09-1989
		ZA 8207601 A	28-09-1983